Lucentis improves anatomic outcomes

Article

Ranibizumab (Lucentis) helps improve anatomic outcomes in patients with neovascular age-related macular degeneration (AMD), according to Nancy HoleKamp, MD speaking at the retina free paper session at the 2006 AAO meeting in Las Vegas.

Ranibizumab (Lucentis) helps improve anatomic outcomes in patients with neovascular age-related macular degeneration (AMD), according to Nancy HoleKamp, MD speaking at the retina free paper session at the 2006 AAO meeting in Las Vegas.

In a retrospective analysis of the Phase III MARINA study results, patients with neovascular AMD who were treated with a 0.5 mg dose of ranibizumab demonstrated improvement in anatomic outcomes that corresponded to improved visual acuity (VA).

Fluorescein angiography (FA) and optical coherence tomography (OCT) were used to assess anatomic changes for patients receiving ranibizumab or sham injection over 24 months for FA and 12 months for OCT, explained Dr Holekamp. The key anatomic endpoints were: mean total lesion area at 24 months; total area of CNV at 24 months; mean area of leakage at 24 months; mean foveal retinal thickness at 12 months.

Ranibizumab was shown to have favourable anatomic outcomes with little growth in the mean total lesion area, no growth of CNV, decreased leakage, and significant thinning of the retina, Dr Holekamp said.

"These anatomic changes were consistent with visual outcomes," she concluded.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.